



Republic of the Philippines  
DEPARTMENT OF HEALTH  
OFFICE OF THE SECRETARY  
**PURCHASE ORDER**  
**Procurement of Diethylcarbamazine Citrate (DEC)**  
IB No. 2018-094

**Eurocare Pharma Inc.**

Km 21 East Service Road, Cupang Muntinlupa City  
Tel No. (02) 623-6721 Fax No. (02) 807-1057  
006-360-258-000

PO No. :

Date:

Mode of Procurement:

GOP-2018-06-115

**JUL 27 2018**  
Competitive Bidding

Sir/Madam:

Please furnish this office of the following articles subject to the terms and conditions contained herein:

Place of Delivery: DOH Warehouse(s) or Service Provider(s) in Metro Manila

Date of Delivery: See delivery schedule listed below

Delivery Term:

Mode of Payment:

Upon Delivery and Acceptance

Item No.	Unit	Description	Quantity	Unit Cost	Amount
1	tablets	<b>Diethylcarbamazine Citrate (DEC)</b> <b>Name of Manufacturer:</b> Dupen Laboratories Pvt. Ltd. <b>Country of Origin:</b> India <b>Technical Specification:</b> <ul style="list-style-type: none"><li>• 50mg tablet</li><li>• Film coated tablet</li></ul> <b>Upon delivery the following shall be complied with:</b> <ul style="list-style-type: none"><li>• <b>Shelf Life:</b> Must have a shelf life of at least <i>twenty four (24) months</i> from the date of manufacture but not less than <i>eighteen (18) months</i> from the date of delivery.</li><li>• <b>Packaging Instructions:</b> Standard packaging of the manufacturer including package insert or encryption/imprint inside the box as approved by PFDA.</li><li>• <b>Labeling Instructions:</b> Standard labeling instruction as approved by PFDA pursuant to Administrative Order No. 2016-0008.</li></ul> <b>In addition to the labelling requirement of FDA:</b> <ul style="list-style-type: none"><li>• On each <b>blister pack/foil strip/bottle, box</b> the following should be legibly imprinted or stickered with non-removable or permanent sticker/label that is binding and with residue and tearing, if removed:<div><b>Philippine Government Property-DOH</b> Not for Sale</div></li><li>• On each <b>corrugated carton</b>, the following should be legibly imprinted or stickered with non-removable or permanent sticker/label that is binding and with residue and tearing, if removed:<div><b>Philippine Government Property-DOH</b> Not for Sale</div></li></ul> <b>Philippine Government Property-DOH</b> Not for Sale Manufacturing Date: _____ Expiration Date: _____ Batch/Lot No.: _____ <ul style="list-style-type: none"><li>• <b>Product Recall/Replacement:</b> The supplier must ensure the quality of drugs and if there will be problems in the quality, the supplier will recall and replace the drugs distributed in the regions and health centers based on the Guidelines on Product Recall, FDA Circular No. 2016-012.</li><li>• <b>Other Requirements for Payment:</b><ol style="list-style-type: none"><li>1. Within a period of thirty (30) days from receipt of delivery, a one hundred percent (100%) payment arrangement shall be made to the company upon receipt of satisfactory results of analysis from PFDA.</li><li>2. If, however, by thirty (30) days from receipt of delivery, PFDA cannot release the result of laboratory analysis, the company shall be paid fifty (50%) of the due amount. The remaining fifty percent (50%) balance is to be paid after obtaining a satisfactory PFDA report of analysis.</li><li>3. The supplier shall be charged of the laboratory testing fee for the test analysis of the delivered drugs and medicines. The payment shall be made directly by the supplier to the PFDA Cashier's Office. Otherwise, the Laboratory Test result will not be released to the Supply Chain Management Service (SCMS) of the Department of Health.</li><li>4. <b>For staggered delivery:</b> Terms of Payment/billing shall be made for each completed delivery and acceptance upon presentation of signed Invoices Receipt and submission of documents as stipulated in the contract.</li></ol></li><li>• <b>The inspection and tests that will be conducted are:</b><ol style="list-style-type: none"><li>1. Upon delivery, the Goods shall undergo preliminary physical inspection by the Inspection Team of the PROCURING ENTITY to ascertain the physical condition and acceptability of the Goods.</li><li>2. The supplier shall promptly replace the equivalent quantity of Goods taken as samples without cost to the PROCURING ENTITY.</li><li>3. Pending PFDA analysis, said products should not be distributed to end-users nor shall it be used until such time it is cleared by PFDA laboratory testing.</li><li>4. If PFDA inspection or results of laboratory analysis show major violations, the entire product line of the drug is temporarily suspended from accreditation, regardless of the batch or lot in question.</li><li>5. All health commodities with failed FDA test analysis shall immediately be pulled out by the suppliers from the DOH warehouse or from the warehouse of the DOH service provider within five (5) working days upon receipt of FDA test result from SCMS.</li></ol>Failure to comply within the prescribed time shall compel this Office to have the subject commodities pulled out by the third party logistics service provider of the DOH with the hauling and freight fees chargeable against the concerned supplies. In the observance of the above-mentioned timeline, please coordinate with the SCMS of the DOH.</li></ul> <b>Delivery Schedule:</b> <b>1st Tranche:</b> 10,546,600 tablets Sixty (60) calendar days upon receipt of approved Notice to Proceed (NTP). <b>2nd Tranche:</b> 10,000,000 tablets One Hundred Twenty (120) calendar days upon receipt of approved NTP. <b>Purpose:</b> For 2018 Procurement of Filariasis Program Note: Subject to the conditions stated in the Bidding Documents	20,546,600	0.353	7,252,949.80
Seven Million Two Hundred Fifty Two Thousand Nine Hundred Forty Nine Philippine Pesos and Eighty Centavos					7,252,949.80



Republic of the Philippines  
DEPARTMENT OF HEALTH  
OFFICE OF THE SECRETARY  
PURCHASE ORDER

Procurement of Diethylcarbamazine Citrate (DEC)

IB No. 2018-094

**Eurocare Pharma Inc.**

Km 21 East Service Road, Cupang Muntinlupa City  
Tel No. (02) 623-6721 Fax No. (02) 807-1057

006-360-258-000

PO No.:

GOP-2018-06-115

Date:

**JUL 27 2018**

Mode of Procurement:

Competitive Bidding

Sir/Madam:

Please furnish this office of the following articles subject to the terms and conditions contained herein:

Place of Delivery: DOH Warehouse(s) or Service Provider(s) in Metro Manila

Delivery Term:

Date of Delivery: See delivery schedule listed below

Mode of Payment:

Upon Delivery and Acceptance

**Liquidated Damages (Section 68 of the Revised IRR of RA9183):** All contracts executed in accordance with the Act and this IRR shall contain a provision on liquidated damages which shall be payable by the contractor in case of breach thereof. For the procurement of Goods, Infrastructure Projects and Consulting Services, the amount of liquidated damages shall be at least equal to one-tenth of one percent (0.001) of the cost of the unperformed portion for every day of delay. Once the cumulative amount of liquidated damages reaches ten percent (10%) of the amount of the contract, the Procuring Entity may rescind or terminate the contract, without prejudice to other courses of action and remedies available under the circumstances.

**Warranty (Section 62 of the Revised IRR of RA 9183):** In order to assure that manufacturing defects shall be corrected by the supplier, a warranty security shall be required from the contract awardee for a minimum period of three (3) months, in the case of Expendable Supplies, or a minimum period of one (1) year, in the case of Non-expendable Supplies, after acceptance by the Procuring Entity of the delivered supplies. The obligation for warranty shall be covered by either retention money in an amount equivalent to at least one percent (1%) but not to exceed five percent (5%) of every progress payment, or a special bank guarantee equivalent to at least one percent (1%) but shall not exceed five percent (5%) of the total contract price. The said amounts shall only be released after the lapse of the warranty period, or, in the case of Expendable Supplies, after consumption thereof. Provided, however, that the supplies delivered are free from patent and latent defects and all the conditions imposed under the contract have been fully met.

Conforme:

By Authority of the Secretary of Health:

**HERMINIGILDO V. VALLE, MD, MPA**  
Undersecretary of Health  
Technical Services Cluster

Signature Over Printed Name of Supplier

Date

Fund Cluster:

Funds Available:

**LORIDA C. RABAGO**

**OIC ACCOUNTING DIVISION**

Regional Laboratory Compound, Rizal Avenue, Sta Cruz, 1003 Manila • Trunk Line 651-7900 local 1108, 1111, 1112, 1113  
Direct Line: 711-9902; 711-9503 Fax: 743-1829 • URL: <http://www.doh.gov.ph>; e-mail: [fdn@do.gov.ph](mailto:fdn@do.gov.ph)

ORS/BURS No.: 02-MIN-2018-07-02019  
Date of the ORS/BURS: 7-27-18

Amount: 7,252,944.50

PS / GOBAC

APPROVED PO / CONTRACT

Received by:

Date: **AUG 28 2018**

BA / GOBAC

RELEASED: PO / CONTRACT

by:

Date: **SEP 03 2018**